Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tremelimumab · Imjudo, CP-675

Monoclonal antibody · Antagonist of CTLA-4 · developed by Astrazeneca

Approved FDA, Oct 2022

AZN Developer

1 Registered trials

What is Tremelimumab?

Tremelimumab-actl is a monoclonal antibody that binds CTLA-4 and blocks its interaction with CD80 and CD86, releasing CTLA-4-mediated inhibition of T-cell activation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Imjudo, CP-675, CP-675206, Ticilimumab
Drug type: Monoclonal antibody
Targets: CTLA-4, CD80 (binding partner it blocks), CD86 (binding partner it blocks)
Mechanism: Antagonist of CTLA-4
Pathways: T-cell activation
Therapy area: Oncology
Developer: Astrazeneca Ab (AZN)
FDA status: Approved as Imjudo (October 21, 2022), BLA761289 · FDA label
UNII: QEN1X95CIX

✅ FDA-approved uses

Unresectable hepatocellular carcinoma (in combination with durvalumab)
Metastatic non-small cell lung cancer with no sensitizing EGFR mutation or ALK genomic tumor aberrations (in combination with durvalumab and platinum-

From the indications section of the FDA label (version of Aug 31, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04585490	Phase 3	Non Small Cell Lung Cancer	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Small Cell Lung CancerNsclcNSCLC, Stage III

Other drugs acting on CTLA4

Ipilimumab FDA approved Botensilimab Phase 2/3 Cadonilimab Early Phase 1 Firastotug Phase 1 Muzastotug Phase 2 Pembrolizumab/Quavonlimab Phase 1/2 Volrustomig Phase 3 Zalifrelimab Phase 1/2

More from Astrazeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Tremelimumab

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z